RE: BioNTech4 Oct 2024 10:24
Duggan's latest investment, in the stock of Summit Therapeutics, has become one of the biggest bets in the industry in recent years. The stock has risen more than 1,000% over the past 12 months, thanks to successful results from an advanced trial that showed its drug, Ivonescimab, beat Merck's (157) blockbuster cancer drug, Keytruda, in patients with a certain type of lung cancer. Duggan, who was already a billionaire before investing in Summit, is now worth about $16 billion, according to Forbes